Stock Events

Stock Events

Assembly Biosciences 

€24.7
38
+€1.35+5.78% Tuesday 19:55

Statistics

Day High
24.8
Day Low
23.35
52W High
33.8
52W Low
9.94
Volume
170
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2025
Next
-0.74
-0.09
0.56
1.2
Expected EPS
-0.5547035
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow V7B.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences is a leading biopharmaceutical company that competes with Assembly Biosciences in the development of treatments for viral diseases, including hepatitis B, which is a key focus area for Assembly Biosciences.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie competes in the pharmaceuticals sector focusing on therapies for chronic diseases, including hepatitis, directly competing with Assembly Biosciences' hepatitis B therapeutic development.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. is involved in the discovery, development, and marketing of drugs for infectious diseases, including hepatitis B, making it a competitor to Assembly Biosciences.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb is a global biopharmaceutical company with a portfolio that includes viral infection treatments, competing with Assembly Biosciences in the hepatitis B market.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals incorporates innovative drug discovery and development, particularly in treating chronic diseases, which puts it in competition with Assembly Biosciences in the field of hepatitis B.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap10.48B
Arrowhead Pharmaceuticals focuses on developing medicines for intractable diseases by silencing the genes that cause them, including hepatitis B, making it a direct competitor to Assembly Biosciences.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its pharmaceutical segment Janssen, develops treatments for infectious diseases, including hepatitis B, positioning it as a competitor to Assembly Biosciences.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.51B
Alnylam Pharmaceuticals is pioneering RNA interference (RNAi) therapeutics, with a focus on liver diseases including hepatitis B, competing with Assembly Biosciences' approach.
Sangamo Therapeutics
SGMO
Mkt Cap55.93M
Sangamo Therapeutics focuses on genomic medicine, including gene editing and gene therapy for liver diseases like hepatitis B, making it a competitor to Assembly Biosciences.

About

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Show more...
CEO
Country
Germany
ISIN
US0453962070

Listings

STU
DE
V7B.STU
MU
DE
V7B.MU
XNAS
US
ASMB
F
DE
V7B.F

0 Comments

Share your thoughts

FAQ

What is Assembly Biosciences stock price today?▼
The current price of V7B.STU is €24.7 EUR — it has increased by +5.78% in the past 24 hours. Watch Assembly Biosciences stock price performance more closely on the chart.
What is Assembly Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Assembly Biosciences stocks are traded under the ticker V7B.STU.
Is Assembly Biosciences stock price growing?▼
V7B.STU stock has risen by +11.01% compared to the previous week, the month change is a -1.2% fall, over the last year Assembly Biosciences has showed a +103.29% increase.
When is the next Assembly Biosciences earnings date?▼
Assembly Biosciences is going to release the next earnings report on May 07, 2026.
What were Assembly Biosciences earnings last quarter?▼
V7B.STU earnings for the last quarter are 1.2 EUR per share, whereas the estimation was -0.74 EUR resulting in a +262.69% surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is Assembly Biosciences located?▼
Assembly Biosciences operates in the Materials sector.
When did Assembly Biosciences complete a stock split?▼
Assembly Biosciences has not had any recent stock splits.